This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Analysts' Actions: BA, EW, ZNGA, JCP, BBY

Stocks in this article: BA EW ZNGA JCP ADBE BBY HGSI IMGN NKE DFS

NEW YORK ( TheStreet) -- CHANGE IN RATINGS

Adobe Systems (ADBE) downgraded at Jefferies to Hold from Buy, Jefferies said. $32 price target. Too much change to navigate comfortably.

Best Buy (BBY) upgraded at Citigroup to Neutral from Sell, Citigroup said. $21 price target. More balanced risk/reward after 35% pullback.

Beneficial Mutual Bancorp (BNCL) downgraded to hold at TheStreet Ratings.

Clean Energy Fuels (CLNE) downgraded to sell at TheStreet Ratings.

Human Genome (HGSI) downgraded at JMP from Outperform to Market Perform, JMP Securities said. Benlysta likely faces an uphill battle to gain adoption for doctors treating lupus.

Immunogen (IMGN) rated new Hold at Cantor. $15 price target. Stock is already factoring in commercial revenue expected from Roche deal.

Nike (NKE) upgraded at McAdams from Sell to Hold, McAdams Wright Ragen said. Stock has pulled back to a fair value.

STOCK COMMENTS / EPS CHANGES

Boeing (BA - Get Report) estimates lowered at UBS through 2013, UBS said. Gauging MAX impact on BCA margins. Neutral rating and $72 price target.

Crane (CR) estimates, target reduced at Keybanc. CR estimates were cut through 2013, Keybanc said. Strong dollar and lower commecial demand could hurt near-term results. Buy rating and new $50 price target.

Ctrip.com International (CTRP) estimates lowered at Oppenheimer through 2013, Oppenheimer said. Impact of the PRC withholding tax. Outperform rating.

Discover Financial Services (DFS) numbers raised at Citigroup. Shares of DFS now seen reaching $35, Citigroup said. Estimates also increased to reflect better card credit. Neutral rating.

Equifax (EFX) estimates, target raised at Credit Suisse. Shares of EFX now seen reaching $50, according to Credit Suisse. Estimates also increased, as the company can likely sustain solid organic sales growth, despite difficult macro conditions. Neutral rating.

Edward Lifesciences (EW - Get Report) target raised at Jefferies. Shares of EW now seen reaching $100, Jefferies said. Positive panel paves way for Sapien Label expansion. Buy rating.

Edwards Lifesciences target boosted at BMO. Shares of EW now seen reaching $94, according to BMO Capital. FDA panel was strongly in favor of approving Cohort A. Market Perform rating.

Jabil Circuit (JBL) numbers cut at Citigroup. Shares of JBL now seen reaching $21, Citigroup said. Estimates also lowered given disappointing outlooks from major customers. Neutral rating.

JC Penney (JCP - Get Report) target cut at Morgan Stanley to $22, according to Morgan Stanley. Survey suggests a weaker consumer pricing environment. Underweight rating.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,672.60 -141.38 -0.79%
S&P 500 2,051.82 -11.33 -0.55%
NASDAQ 4,757.8790 +7.4820 0.16%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs